Right Versus Left Apical Transvenous Pacing for Patients With Preserved Left Ventricular Systolic Function Study

NCT ID: NCT01535404

Last Updated: 2016-05-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2016-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare chronic (1-year) effects on left ventricular ejection fraction resulting from transvenous pacing of the right ventricular apex (RVA) versus the left ventricular apex (LVA) in patients with preserved or mildly reduced left ventricular systolic function (\>= 45%).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is well established that chronic right ventricular apical pacing has an adverse effect on left ventricular systolic function. An alternative is pacing the left ventricular apex, which has shown more favourable results in terms of left ventricular pump function than the RVA in small series. The left ventricular apex may be paced via the coronary sinus tributary (e.g. in the anterior cardiac vein). Our study will compare effects of these two pacing sites on left ventricular ejection fraction measured by 3D-echocardiography.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bradyarrhythmia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Right ventricular apex pacing

Group Type ACTIVE_COMPARATOR

Implantation procedure for a St-Jude Medical pacemaker system with right ventricular apex pacing

Intervention Type DEVICE

Implantation procedure for a St-Jude Medical pacemaker system with a transvenous ventricular and if applicable a right atrial lead

Left ventricular apex pacing

Group Type EXPERIMENTAL

Implantation procedure for a St-Jude Medical pacemaker system with left ventricular apex pacing

Intervention Type DEVICE

Implantation procedure for a St-Jude Medical pacemaker system with a transvenous left ventricular (coronary sinus) and if applicable a right atrial lead

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Implantation procedure for a St-Jude Medical pacemaker system with right ventricular apex pacing

Implantation procedure for a St-Jude Medical pacemaker system with a transvenous ventricular and if applicable a right atrial lead

Intervention Type DEVICE

Implantation procedure for a St-Jude Medical pacemaker system with left ventricular apex pacing

Implantation procedure for a St-Jude Medical pacemaker system with a transvenous left ventricular (coronary sinus) and if applicable a right atrial lead

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Requirement for ventricular pacing according to current guidelines (including chronic atrial fibrillation)
* Anticipated \>=50% daily ventricular pacing
* LVEF \>=45% as evaluated by 2D-echocardiography, 3D-echocardiography, magnetic resonance imaging or by radionuclide/contrast ventriculography
* Minimum age of 18 years, and at least 1 year life expectancy

Exclusion Criteria

* Prior tricuspid valve replacement (annuloplasty is permitted)
* Intrinsic rhythm \< 30bpm
* Patients with permanent atrial fibrillation who undergo ablation of the atrioventricular node.
* Echocardiographic window of insufficient quality for measuring LVEF
* Life expectancy of \< 1year
* Pregnancy (women of childbearing potential will undergo pregnancy testing)
* Unable of unwilling to sign a patient informed consent form
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Abbott Medical Devices

INDUSTRY

Sponsor Role collaborator

Haran Burri, MD

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Haran Burri, MD

Assoc. Prof.

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Haran Burri, Assoc. Prof.

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Geneva

Angelo Auricchio, Prof.

Role: PRINCIPAL_INVESTIGATOR

Fondazione Cardiocentro Ticino (Lugano)

Christian Sticherling, Prof.

Role: STUDY_CHAIR

University Hospital of Basel

Paul Erne, Prof.

Role: STUDY_CHAIR

Luzerner Kantonsspital

Peter Ammann, PD Dr.

Role: STUDY_CHAIR

Cantonal Hospital of St. Gallen

Frits Prinzen, Dr.

Role: STUDY_CHAIR

Cardiovascular Research Institute, University of Maastricht

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cardiovascular Research Institute, University of Maastricht

Maastricht, , Netherlands

Site Status

University Hospital of Basel

Basel, Canton of Basel-City, Switzerland

Site Status

University Hospital Geneva

Geneva, Canton of Geneva, Switzerland

Site Status

Kantonsspital Luzern

Lucerne, Canton of Lucerne, Switzerland

Site Status

Kantonsspital St-Gallen

Sankt Gallen, Canton of St. Gallen, Switzerland

Site Status

Cardiocentro Ticino (Lugano)

Lugano, Canton Ticino, Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CRM-CH-Riv01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Biventricular Alternative Pacing
NCT00559143 WITHDRAWN PHASE4
Short Atrioventricular Delay Pacing
NCT01233661 WITHDRAWN NA